Healthcare systems lag behind rapid expansion of GLP-1 therapies, raising care and trust challenges

GLP-1 drugs have demonstrated that pharmacological treatment can effectively reduce obesity, and regulators have now approved them for additional uses such as cardiovascular risk reduction, metabolic-associated steatohepatitis and sleep apnea.

Pharma companies face three key hurdles: showing that these medicines provide benefits beyond weight loss, creating a care infrastructure that can support patients for years rather than months, and building trust in a market that is evolving quickly.

The pipeline is widening with new classes like triple agonists, amylin‑based combinations and oral formulations, each adding new patient groups, evidence requirements and operational complexity for health systems.

Payers remain uncertain about affordability, appropriate use and long‑term coverage, while primary‑care providers are being asked to manage complex chronic metabolic conditions without sufficient support structures.